natgillin/translations-raw huggingface dataset:
The technique takes place in five steps: equilibration of the column to pH and ionic conditions ideal for target protein binding; reversible adsorption of the sample to the column through counterion displacement; introduction of elution conditions that change the buffer's pH or ionic strength in order to displace bound proteins; elution of substances from the column in order of binding strength (weakly-bound proteins are eluted first); and re-equilibration of the column for subsequent purifications. 
Ova se tehnika odvija u petkoraka; ekvilibracija kolone u ionske uvjete i pH koji su idealni za vezanje ciljnog proteina; reverzibilna adsorpcija uzorja na kolonu preko izbacivanja protuiona; uvođenje eluacijskih uvjeta kojima se mijenja pH pufera ili ionska jakosr sa ciljem otpuštanja cezanih proteina; eluacija supstancija s kolone redoslijedom jakosti vezanja (slabo-vezani proteini eluiraju prvi); re-ekvilibracija kolone za naknadna pročipćavanja.
The blister pack according to Claim 16, in which said shaped layer (8) comprises at least a second layer (8B) located beneath said layer (8A). 
Blister pakiranje prema 14. zahtjevu, naznačeno time da navedeni oblikovani sloj (8) sadrži najmanje jedan drugi sloj (88) koji se nalazi ispod navedenog sloja (8).
The pharmaceutical compositions of the FGF-21 muteins of the present invention may be administered by any means known in the art that achieve the generally intended purpose to treat type II diabetes, obesity, or metabolic syndrome. 
Farmaceutski pripravak namijenjen upotrebi u liječenju pacijenta koji pokazuje jedno ili više od pretilosti, dijabetesa tipa II, otpornost na inzulin, hiperinzulinemiju, intoleranciju glukoze, hiperglikemiju, ili metabolički sindrom, koji sadrži sljedeće:
A process according to claims 15 or 16 wherein step w/y is carried out by reacting a compound of formula IIa or IIb with 2-bromo-4-fluorophenol or 2-bromo-4-fluorophenyl acetate in basic conditions in the presence of a palladium catalyst under Heck C-C couplings. 
Postupak u skladu sa zahtjevima 15 ili 16, naznačen time da se koraci w/y provode reakcijom smjese formule Ila ili Ib sa 2-bromo-4-fluorofenolom ili 2-bromo-4-fluorofenil acetatom u osnovnim uvjetima, u nazočnosti paladijevog katalizatora prema CC Heckovim vezivanjem.
Process according to claim 5, which further comprises adding water to the reaction mixture, after conclusion of the reaction, to precipitate atorvastatin tert.-butyl ester (II). 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se dodatno sastoji u dodavanju vode u reakcijsku smjesu, nakon dovršenja reakcije, kako bi se istaložilo tert-butilni ester atorvastatina (II).
The resulting solution was stirred and a precipitate began to form within one minute. 
Rezultirajuća otopina se miješa i unutar minute započne formiranje precipitata.
The chemically modified glycosaminoglycans according to claim 3, wherein the modified glucosamines are presented as signals at 5.95 ppm and 6.15 ppm in an 1H-NMR spectrum. 
Kemijski modificirani glikozaminoglikani prema zahtjevu 3, naznačeni time da se modificirani glukozamini nalaze kao signali na 5,95 ppm i 6,15 ppm u 1H-NMR spektru.
is hydrogen, or C1-C6 alkyl optionally substituted by hydroxy; is fluoro; 
R1 je vodik, ili C;-Cg alkil prema potrebi supstituiran s hidroksi;
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje kad je testiran u komparativnoj kliničkoj studiji je bioekvivalentan trgovačkom proizvodu OxyContin"".
The method of claim 15, wherein the at least two pump segments are configured to be angularly positioned relative to the roller head when the at least two pump segments engage the roller head. The method of claim 15, wherein the at least one sheet includes an elastomeric sheet. 
Postupak prema zahtjevu 11, naznačen time, da su najmanje dva segmenta (103) sisaljke oblikovani za kutni položaj u odnosu na glavu valjka (203) kada najmanje dva segmenta sisaljke zahvaćaju na glavu valjka.
In a special aspect the present invention discloses the treatment of a type I or type III allergy, autoimmune diseases or septic shock with a pharmaceutical preparation comprising escin. BRIEF DESCRIPTION OF THE DRAWINGS 
Upotreba temeljem bilo kojeg od zahtjeva 1 do 4, naznačena time što je bolest alergija tipa I ili tipa III ili septički šok, poželjno alergija tipa I.
A compound of formula: or a pharmaceutically acceptable salt thereof. 
Spoj iz patentnog zahtjeva 1 koji je spoj formule: aa
Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ATORVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4- inhibitora, jednu količinu inhibitora reduktaze HMG-CoA 1 barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDEA-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je ATORVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina 1 druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
The method of claim 7, further comprising cooling the reaction mixture to a temperature of between 5 degrees Celsius and ambient temperature after lowering the pH of the reaction mixture. 
Postupak prema zahtjevu 12 ili zahtjevu 14, naznačen time da dodatno nakon koncentriranja reakcijske smjese, ili nakon snižavanja pH reakcijske smjese sadrži hlađenje reakcijske smjese do temperature od između 5 stupnjeva Celzija i temperature okoline.
The transdermal delivery device of claim 1, wherein the opioid antagonist becomes releasable if the transdermal delivery device is chewed, soaked, punctured, torn, or subjected to any other treatment which disrupts the integrity of the microspheres. The transdermal delivery device of claim 1, wherein the effect of the opioid agonist is at least partially blocked when the delivery device is chewed, crushed or dissolved in a solvent, or subject to any other treatment which disrupts the integrity of the microspheres, and administered orally, intranasally, parenterally or sublingually. 
Uređaj za transdermalno davanje prema bilo kojem od zahtjeva 1 do 3, naznačen time da se opioidni antagonist može osloboditi ako se uređaj za transdermalno davanje žvače, kvasi, buši, trga, ili podvrgava bilo kakvom drugom postupku koji narušava integritet mikrosfera; i/ili pri čemu se učinak opioidnog agonista barem djelomično blokira kada se uređaj za davanje žvače, gnječi ili rastapa u otapalu, ili podvrgava bilo kakvom drugom postupku koji narušava integritet mikrosfera, te se primjenjuje oralno, intranazalno, parenteralno ili sublingvalno.
A solution of 2-azidoethanol (160 g) in tetrahydrofuran (300 ml) was added over 40 minutes to a suspension of sodium hydride (114 g; 80% dispersion in oil) in tetrahydrofuran (500 ml). 
CR3OCH,CA2N3 Otopina 2-azidoetanola (160 ml) u tetrahidrofuranu (300 ml) dodaje se tijekom 40 minuta suspenziji natrij-hidrida (114 g; 80% disperzija u ulju) u tetrahidrofuranu (500 ml).
in combination with an additional therapeutic agent, wherein said additional therapeutic agent inhibits a base excision repair protein; and wherein the base excision repair protein is PARP1 or PARP2; 
u kombinaciji s dodatnim terapeutskim sredstvom, naznačen time što navedeno dodatno terapeutsko sredstvo inhibira protein za reparaciju isijecanjem baza; i gdje je protein za reparaciju isijecanjem baza PARP1 ili PARP2;
The antibody or antigen binding portion thereof according to any of claims 1-15, comprising a full length light chain amino acid sequence having at least 95 percent sequence identity to SEQ ID NO: 125 and a full length heavy chain amino acid sequence having at least 95 percent sequence identity to SEQ ID NO: 114. 
16. Protutijelo ili njegov dio koji veže antigen prema bilo kojem od zahtjeva 1-15, naznačeno time da sadrži sekvencu amino kiseline lakog lanca pune duljine koja ima barem 95 posto identičnosti sekvence sa SEQ ID NO: 1251 sekvencu amino kiseline teškog lanca pune duljine koja ima barem 95 posto identičnosti sekvence sa SEQ ID NO: 17.
The reaction of process (m) is conveniently carried out in the presence of an inert solvent or diluent (for example the inert solvents and diluents described in processes (a) and (c), such as acetonitrile, N,N -dimethylacetamide, methanol, ethanol or methylene chloride). 
Reakcija u postupku (m) se poželjno provodi u prisutnosti inertnog otapala ili razrjeđivača (primjerice inertnih otapala ili razrjeđivača opisanih za postupak (a) i (c), poput acetonotirila, N,N-dimetilacetamida, metanola. etanola ili metilenklorida).
wherein, when the intra prediction mode is a horizontal mode, the second scan pattern is a vertical scan. 
Uređaj prema zahtjevu 1, naznačen time da kada je način unutarokvirnog predviđanja horizontalni način, obrazac skeniranja je vertikalni obrazac skeniranja.
reacting the compound of formula IV as obtained in step a) with a thiophenol to obtain a compound of formula V 
OH b) reakcije spoja formule IV kakav je dobiven u koraku a) sa tiofenolom da bi se dobio spoj formule V
The composition according to claim 1, characterized in that the polyalkoxy group of the polyalkoxyalkane is a polyethoxy- and/or polypropoxy- and/or polybutoxy- and/or a mixture thereof, wherein the number of ethoxy groups ranges from 15 to 55, preferably from 25 to 45, even more preferably from 20 to 30. 
Sredstvo prema zahtjevu 1, naznačeno time što polialkoksi skupina u polialkoksialkanu jest polietoksi i broj etoksi skupina je u rasponu od 15 do 55, poželjno od 25 do 45, poželjnije od 20 do 30.
An implantable prosthetic device (100) comprising: 
Protetski zalistak koji se može implantirati, koji sadrži:
The therapeutic nanoparticle of any of embodiments 1-71, 104, or 105, wherein a targeting ligand is additionally present and is PLA-PEG-GL, wherein GL has the following structure: 
Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačena time što dodatno sadrži ciljajući ligand, koji je PLA-PEG-GL., gdje GL ima sljedeću strukturu:
The microorganism according to claim 5, wherein said microorganism is selected from the group consisting of Clostridium acetobutylicum, Clostridium beijerinckii, Clostridium saccharoperbutylacetonicum, and Clostridium saccharobutylicum. 
Mikroorganizam u skladu s patentnim zahtjevom 5, naznačen time, da je navedeni mikroorganizam odabran između Clostridium acetobutylicum, Clostridium beijerinckii, Clostridium saccharoperbutylacetonicum, Clostridium saccharabutylicum.
A composition formulated for oral ingestion by a subject, said composition comprising an effective amount of one or more channel activators selected from TRPV1 channel activators, TRPA1 channel activators, and ASIC channel activators for use in a method for treating muscle cramps, musculoskeletal irritability, or for improving muscle recovery in a subject in need thereof, wherein said composition is a liquid, beverage, gel, solid, semi-solid, chewing gum, or spray, wherein said composition has a pH greater than about 3.5, and wherein said composition comprises an effective amount of two or three different TRP channel activators independently selected from: 
Pripravak formuliran za oralno gutanje od strane subjekta, te navedeni pripravak sadrži učinkovitu količinu jednog ili više aktivatora kanala koji su odabrani od TRPVI aktivatora kanala, TRPA1 aktivatora kanala, te ASIC aktivatora kanala za upotrebu u postupku za liječenje mišićnih grčeva, mišićno-skeletne nadraženosti, ili za poboljšanje oporavka mišića kod subjekta kojem je to potrebno, pri čemu je navedeni pripravak tekućina, napitak, gel, čvrsta tvar, polu-čvrsta tvar, guam za žvakanje, ili sprej, pri čemu navedeni pripravak ima vrijednost pH koja je veća od 3,5, pri čemu navedeni pripravak sadrži učinkovitu količinu dva ili tri različita aktivatora TRP kanala, koji su neovisno odabrani od:
The method of claim 13, wherein a sodium level within the precursor material is less than 500 ppm. 
Postupak prema zahtjevu 13, u kome je razina natrija unutar prokursor materijala manja od 500 ppm.
A method of treating a patient that is suffering from a disease or disorder that is selected from a pain disorder, a depressive disorder, an affective disorder, attention deficit hyperactivity disorder, a cognitive disorder, stress urinary incontinence, chronic fatigue syndrome, obesity, vasomotor symptoms associated with menopause, chronic low back pain, and osteoarthritis, comprising administering a therapeutically effective amount of a compound of formula: where a is 0, 1, 2, 3, or 4; each R1 is independently halo or trifluoromethyl; R3 is hydrogen, halo, or —C1-6alkyl; R4, R5, and R6 are independently hydrogen or halo; or a pharmaceutically acceptable salt thereof. 
Spoj Formule 1: či ili njegova sol, naznačen time da je: L bromo, jodo, ili-OS(O>)-R, gdje je R-C,alkil ili fenil, a fenil je po izboru supstituiran s -C,valkil, halo ili nitro; a je 0, 1, 2, 3, ili 4, svaki R' je neovisno halogen ili trifluorometil, a P je amino-zaštitna skupina odabrana iz t-butoksikarbonil, tritil, benziloksikarbonil, 9-fluorenilmetoksikarbonil, formil, trimetilsilil 1 t-butildimetilsilil.
to an activated cysteinamide through the Pro of the 2-6 eptifibatide sequence, thereby forming the 2-7 eptifibatide sequence. 
HR P20110812 TI na aktivirani reziduum cisteinamida putem rezidua Pro fragmenta 2-6 eptifibatida, čime se formira fragment 2-7 eptifibatida.
represents CR2 or nitrogen, 
A; predstavlja CR2 ili dušik,
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound chlorothalonil. 
UA naznačen time da je R, difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj biksafen.
and optical isomers, pharmaceutically acceptable salts, hydrates, solvates, and polymorphs thereof, with the proviso that the compound of formula (I) does not represent the compound (6-Bromo-pyrazolo[1,5-a]pyrimidin-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone. 
i njihovim optičkim izomerima, farmaceutski prihvatljivim solima, hidratima, otopinama, polimorfima, pod uvjetom da spoj iz formule (I) ne predstavlja spoj (6- bromo- pirazolo [1,5- a] pirimidin- 2- il)- (3,4- dihidro- 1H- izokvinolin- 2- il)- metanona.
The method according to claim 2, wherein the photovoltaic collectors are positioned horizontally. The method as claimed in claim 1, further comprising measuring the temperature of the crops, the orientation of the photovoltaic collectors being controlled at least depending on the temperature measured. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što obuhvaća mjerenje temperature usjeva, orijentacija kolektora se kontrolira barem ovisno o izmjerenoj temperaturi, a temperatura se mjeri pomoću najmanje jedne infracrvene video kamere.
In another aspect of the present invention, the temperature in the step of contacting may be in the range 200-650° C., such as in the range 200-450° C., and preferably in the range 200-374° C., and even more preferably in the range 250-374° C., such as in the range 275-350° C. By keeping these low temperatures the conversion process is using less energy in converting the same amount of organic material than at higher temperatures. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je temperatura u koraku dovođenja u dodir u rasponu od 200-650"C, kao što je raspon od 200-450*C, a poželjno raspon od 200-374"C, a još poželjnije u rasponu od 250-374"C, kao što je raspon 275-350*C.
The organic portions are combined and washed with water (2×200 ml). 
Organski dijelovi se sjedine i isperu s vodom (2 x 200 ml).
The method according to claim 2, wherein said disease is myeloid metaplasia with myelofibrosis (MMM). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj mijeloidna metaplazija sa mijelofibrozom (MMM).
is selected from the group consisting of D-Lys, D-Orn, Lys, and Orn; and X4 is selected from the group consisting ofD-Asp, D-Glu, Asp, and Glu; or 
(1) X, je izabran iz grupe koja se sastoji od D-Lys, D-Orn, Lys i Orn; i X, je izabran iz grupe koja se sastoji od D- ASsp, D-Glu, Asp i Glu; ili
Panel, characterized in that it combines the characteristics of one or more of the preceding claims in itself. Panel according to any of the preceding claims, characterized in that at least said coupling parts (8-9), which are of the type allowing to couple two of such panels (1) to each other by means of a downward movement of one panel in respect to the other, are realized at least partially and preferably entirely in soft PVC. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, naznačena time da drugi sistem za zaključavanje sadrži dijelove (26, 27) za zaključavanje koji se nalaze odmah pored proksimalnog kraja donjeg kukastog dijela (18) 1 distalnog kraja gornjeg kukastog dijela (19), redom; i da je barem jedan od navedenih dijelova (26, 27) za zaključavanje drugog sistema za zaključavanje napravljen od mekog PVC-a.
A pharmaceutical preparation comprising at least 106 mesenchymal stromal cells and a pharmaceutically acceptable carrier, wherein the mesenchymal stromal cells are differentiated from a hemangioblast cell. 
Postupak dobivanja mezenhimnih stromalnih stanica, naznačen time što se sastoji u uzgoju hemangioblasta u uvjetima u kojima se stanice diferenciraju u mezenhimne stromalne stanice.
The process according to claim 2, wherein the metallation agent is n-butyl lithium. 
Postupak prema bilo kojem od zahtjeva 2-4, gdje sredstvo za dodavanje atoma metala n-butil litij.
a quantization unit (130) configured to quantize the transform block to generate a quantized transform block using a quantization step size; 
inverznu kvantizacijsku jedinica (230) konfiguriranu da inverzno kvantizira kvantizirani transformacijski blok koristeći veličinu koraka kvantizacije da generira blok transformacije;
An antibody of any one of claims 1-7, a conjugate of claim 8 or a pharmaceutical composition of claim 9 for use in a method of treating or preventing a cancer disease or disorder involving a cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface in a subject. 
Antitijelo suglasno bilo kojem od zahtjeva 1-11, konjugat suglasno zahtjevu 12 ili farmaceutska kompozicija suglasno zahtjevu 13, za primjenu u postupku tretiranja ili prevencije kancerske bolesti ili poremećaja povezanih sa stanicama koje eksprimiraju CLDN6 i koje su naznačene asocijacijom CLDN6 na staničnoj membrani stanica subjekta.
The system of claim 26 wherein the peristaltic pump is reversible. 
Sustav prema zahtjevu 26, naznačen time što je peristaltička pumpa reverzibilna.
a first soluble TNF-related apoptosis-inducing ligand (TRAIL) cytokine domain, 
(1) prvu topljivu citokinsku domenu iz TNF obitelji,
Examples of such pathologies are psychiatric and neurological disorders; neurodegenerative disorders; metabolic disorders; addiction, dependence, abuse relapse and related disorders; bladder and gastrointestinal disorders; hepatic diseases such as steatosis; non-alcoholic steatohepatitis (NASH), liver cirrhosis; alcoholic steatosis; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; obesity; autoimmune hepatitis and encephalitis; pain or reproductive disorders and skin inflammatory and fibrotic diseases. 
Tvar za uporabu u skladu s patentnim zahtjevom 11, pri čemu je navedena patologija odabrana iz grupe koja se sastoji od psihijatrijskih 1 neuroloških poremećaja, neurodegenerativnih poremećaja, metaboličkih poremećaja, loših navika, ovisnosti, relapsa zlouporabe i povezanih poremećaja, poremećaja mjehura i hastrointestinalnih poremećaja, bolesti jetre kao što je steatoza, nealkoholnog steatohepatitisa (NASH), ciroze jetre, alkoholne steatoze, upalnih bolesti, kardiovaskularnih bolesti, neuropatija, glaukoma, spastičnosti, raka, osteoporoze, pretilosti, autoiminog hepatitisa 1 encefalitisa, boli ili reproduktivnih poremećaja i upalnih 1 fibrotičnih bolesti kože.
Hardening said mortar setting free said opposite sides of said elements of transparent to light material, suitable to form the inlet and the outlet of said opening, and taking out the finished panel from the formwork. Method for producing a panel as claimed in claim 1 characterized by 
€) očvršćavanjem spomenutog morta, pri čemu su spomenute suprotne strane spomenutih elemenata od materijala prozirnog za svijetlost, koji su prilagođeni za formiranje ulaza i izlaza spomenutog otvora, ostale slobodne 1 vađenjem gotove ploče iz okvira.
The isolated antigen binding protein of claim 15, wherein the monoclonal antibody comprises a) a light chain comprising a light chain variable domain comprising the amino acid sequence as set for in SEQ ID NO:363 and a lambda light chain constant domain comprising the amino acid sequence as set forth in SEQ ID NO:369; and b) a heavy chain comprising a heavy chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:361 and an IgG2 heavy constant domain comprising the amino acid sequence as set forth in SEQ ID NO:365. 
Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, pri čemu je navedeno anti-TSLP ljudsko protutijelo monoklonsko protutijelo. 15. Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, pri čemu navedeno anti-TSLP ljudsko protutijelo sadrži a) laki lanac koji sadrži varijabilnu domenu lakog lanca koja sadrži aminokiselinski slijed pretpostavljen u SEQ ID NO:363 i konstantnu domenu lambda lakog lanca koja sadrži aminokiselinski slijed pretpostavljen u SEQ ID NO:
The method of claim 1, wherein said antibody polypeptide comprises a variable domain that has a binding specificity to CD28 and that differs from the amino acid sequence of dAb 1h-239-891(D70C) (SEQ ID NO: 543) by 8 or fewer amino acid positions. 
Antitijelo sa jednim imunoglobulinskim varijabilnim domenom iz patentnog zahtjeva 3 ili patentnog zahtjeva 5, koje sadrži aminokiselinsku sekvencu sa SEQ ID NO:543, gdje PEG je razgranati PEG od 40 kD, i gdje je PEG polimer vezan za D70C cisteinski ostatak.
Note that such deflectable sealing member 8 can be placed at any position onto the capsule 1 as long as the position is adapted for an exterior sealing engagement of the sealing member 8 and the enclosing member 9 between the water injector 14 and the perforations in the foil member 5. 
Treba napomenuti da takav savitljivi element za nepropusno zatvaranje 8 može biti stavljen na bilo koji položaj na čahuri 1 sve dok je položaj prilagođen za vanjsko brtvljenje elementa za nepropusno zatvaranje 8 i elementa za obuhvaćanje 9 između injektora za vodu 1 perforacija na elementu od folije 5.